A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsUsing the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?Schizophrenia pathophysiology: are we any closer to a complete model?The treatment of cognitive impairment in schizophrenia.Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions.Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors.Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans.The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study.Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.Phosphodiesterase type 5 and cancers: progress and challenges.From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
P2860
Q22241447-E6802FA2-A5B7-4ACF-8AF6-A5E298348758Q30489404-E50A1C81-FA32-4352-84DC-08B86DE1EAC2Q30536299-ABCD5EDF-6C09-4C8C-B153-280E91F749ACQ37484017-D036D24B-A018-415C-879A-9A896880B3C2Q37813206-8B01058B-A0BA-4C02-A39A-795BD93066D5Q37867702-3BAF140F-834E-491E-843F-2E3672555B28Q37903037-84B63A6C-CD9D-4B0D-9F98-35B92FFF0B96Q38173359-1E63265E-1E19-4EBF-A681-D8BF18900D99Q38643963-B5494255-F0BE-41AA-8EC4-9F75EBC5F2AEQ44240737-974F4487-FBE4-4EEC-8188-DA565494D749Q46077750-9F853C6A-C3A3-492A-AF32-3DB7165A33AAQ46986165-AE78E42C-C99F-49FB-8DF3-E03129C60976Q47171803-4E81287D-1A51-42BA-A4D5-6FE7ACCDDB84Q47611446-2706B419-4E1F-41CA-AAD1-0C7FB1A86848Q48394157-308E33D5-4E08-4969-977D-C3C9A4B02C6FQ50803548-599887C9-4A00-46EB-9AFD-0B0CADCC37FEQ54975082-18677E0F-DA96-4C87-A288-57934D564FF9Q58561523-BA55DCBA-7D3F-49D5-A9BB-4DD6C15470AD
P2860
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@en
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@nl
type
label
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@en
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@nl
prefLabel
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@en
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@nl
P2093
P2860
P1433
P1476
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
@en
P2093
A Eden Evins
Corinne Cather
David C Henderson
Jared P Walsh
Melissa A Culhane
Oliver Freudenreich
P2860
P2888
P304
P356
10.1007/S00213-008-1278-5
P577
2008-08-21T00:00:00Z